Eversept Partners, LP Vaxcyte, Inc. Transaction History
Eversept Partners, LP
- $993 Million
- Q2 2025
A detailed history of Eversept Partners, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 1,298,514 shares of PCVX stock, worth $55 Million. This represents 4.25% of its overall portfolio holdings.
Number of Shares
1,298,514
Previous 557,070
133.1%
Holding current value
$55 Million
Previous $21 Million
100.69%
% of portfolio
4.25%
Previous 2.33%
Shares
13 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$622 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$508 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$507 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$421 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$254 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.51B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...